Company: NCEL
Filing Date: 2025-03-31
Form Type: 6-K
Source: 0001213900-25-025839
Chunk: 0

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of March 2025 (Report No. 2)

Commission file number: 001-39957

NLS PHARMACEUTICS LTD.

(Translation of registrant’s name into English)

The Circle 6

8058 Zurich, Switzerland

(Address of principal executive offices)</div>

Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.

<div align='center'>Form 20-F ☒ Form
40-F ☐

CONTENTS</div>

Private Placement Financing Transaction in the amount of $3 million

On March 27, 2025, NLS Pharmaceutics
Ltd, or the Company, entered into a securities purchase agreement, or the Securities Purchase Agreement, with three accredited investors.
Pursuant to the terms of the Securities Purchase Agreement, the Company agreed to issue and sell to the investors, in a private placement
offering, or the Offering, 1,212,122 preferred shares, par value CHF 0.03 per share, or the Preferred Shares, with a conversion price
of $1.65 per share, for aggregate gross proceeds of $2 million. Pursuant to the terms of the Securities Purchase Agreement, the investors
may purchase up to $1 million of additional Preferred Shares on identical terms as the initial closing, subject to the Company obtaining
shareholder approval. The Offering closed on March 28, 2025.

The Securities Purchase Agreement
contains customary representations and warranties and agreements of the Company and the investor and customary indemnification rights
and obligations of the parties. In addition, the Company agreed to issue the lead investor up to 435,000 preferred shares (or their equivalent)
to compensate the investor for certain price protection issuances and registration obligations.

The initial closing of the Offering resulted in gross proceeds to the Company of to $2 million. The Company
intends to use the net proceeds from the Offering for working capital and general corporate purposes, including for expenses relating
to its merger with Kadimastem Ltd.

The securities are being offered
pursuant to an exemption from the registration requirements under Section 4